Roivant starts new Phase 2b/3 trial for hair loss drug, TED study fails
Tweet Send to a Friend
Roivant Sciences (NASDAQ: ROIV) announced it has begun enrolling patients in a Phase 2b/3 study of brepocitinib for lichen planopilaris ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
